OREX revised some Contrave efficacy metrics downward in an 8-K filing today: http://sec.gov/Archives/edgar/data/1382911/000119312510082049/d8k.htm Not issuing a PR for such consequential information is an odd decision, IMO. These are the slides from OREX’s investor presentation today: http://sec.gov/Archives/edgar/data/1382911/000119312510082049/dex991.htm